TRYPTAN 250 MG
TRYPTOPHAN : 250 MG · DIN 02239326 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is TRYPTAN?
TRYPTAN 250 MG contains TRYPTOPHAN : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02239326, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRYPTAN used for?
TRYPTAN is indicated as a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239326 |
|---|---|
| Brand name | TRYPTAN |
| Generic / active ingredient | TRYPTOPHAN : 250 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX02 TRYPTOPHAN |
| AHFS class | 28:16.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jun-2021 |
| Original market date | 1999-01-06 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02239326 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2239326 |
| Brand name | TRYPTAN |
| Active ingredient / INN | TRYPTOPHAN : 250 MG |
| ATC code | N06AX02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| AHFS class | 28:16.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
How is it stored and handled?
Store at controlled room temperature (15 - 30ºC). Protect from heat and light.
How is it supplied?
500 mg capsules: Bottles of 100 capsules. 250 mg tablets: Bottles of 100 tablets. 500 mg tablets: Bottles of 100 tablets. 750 mg tablets: Bottles of 100 tablets. 1 g tablets: Bottles of 100 tablets.
Which pack is which?
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 500 mg capsules: Bottles of 100 capsules. 250 mg tablets: Bottles of 100 tablets. 500 mg tablets: Bottles of 100 tablets. 750 mg tablets: Bottles of 100 tablets. 1 g tablets: Bottles of 100 tablets. |
| Storage | Store at controlled room temperature (15 - 30ºC). Protect from heat and light. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N06AX02 TRYPTOPHAN. 11 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TRYPTOPHAN | 1 G | TABLET | APOTEX INC | MARKETED | DIN 02248539 |
| APO-TRYPTOPHAN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02248538 |
| APO-TRYPTOPHAN | 500 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02248540 |
| APO-TRYPTOPHAN | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02458721 |
| TEVA-TRYPTOPHAN | 500 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02240334 |
| TEVA-TRYPTOPHAN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02240333 |
| TRYPTAN | 1 G | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00654531 |
| TRYPTAN | 500 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00718149 |
| TRYPTAN | 500 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02029456 |
| TRYPTAN | 750 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02239327 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.